Copyright
©The Author(s) 2024.
World J Transplant. Sep 18, 2024; 14(3): 93209
Published online Sep 18, 2024. doi: 10.5500/wjt.v14.i3.93209
Published online Sep 18, 2024. doi: 10.5500/wjt.v14.i3.93209
Table 1 Recommended approaches for cytomegalovirus prevention in liver transplantation[17]
CMV serostatus | Comments |
D/R; low risk | Antiviral prophylaxis: CMV D-/R- LT recipients do not require anti-CMV prophylaxis; but if they are HSV1-or HSV2-seropositive, they should receive anti-HSV prophylaxis during the early period after LT (strong, high) |
Alternative: (1) Pre-emptive therapy (if higher risk, i.e., significant transfusions): If blood transfusion is required, CMV D/R patients should receive; and (2) CMV-seronegative or leuko-reduced blood products (strong, high) | |
D+/R+; D/R+; intermediate risk | Antiviral prophylaxis: (1) Drugs: valganciclovir1 900 mg po every 24 h; (2) ganciclovir 5 mg / kg (iv) 1×/d; and (3) duration: 3 months (strong, high) |
Alternative: (1) Pre-emptive therapy (if logistic support is available) (strong, high); (2) weekly CMV QNAT (or pp65 antigenemia) for 12 wk after LT; and (3) if a positive CMV threshold is reached, treat with valganciclovir 900 mg (po) BID (preferred), or ganciclovir 5 mg/kg (iv) every 12 h until negative test | |
D+/R; high risk | Antiviral prophylaxis: (1) Drugs: valganciclovir 900 mg (po) every 24 h; (2) ganciclovir 5 mg/kg (iv) 1×/d; and (3) duration: 3 mo (strong, high), 6 mo (strong, moderate) |
Alternative: (1) Pre-emptive therapy (if logistic support is available) (strong, high); (2) weekly CMV QNAT (or pp65 antigenemia) for 12 wk after LT; and (3) if a positive CMV threshold is reached, treat with valganciclovir 900 mg (po) BID (preferred), or ganciclovir 5 mg/kg (iv) every 12 h until negative test |
- Citation: Yilmaz ZB, Memisoglu F, Akbulut S. Management of cytomegalovirus infection after liver transplantation. World J Transplant 2024; 14(3): 93209
- URL: https://www.wjgnet.com/2220-3230/full/v14/i3/93209.htm
- DOI: https://dx.doi.org/10.5500/wjt.v14.i3.93209